PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies
Open Access
- 17 July 2024
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (7) , e13865
Abstract
The urgent need for safe, efficacious, and accessible drug treatments to treat coronavirus disease 2019 (COVID‐19) prompted a global effort to evaluate drug repurposing opportunities. Pyronaridine and amodiaquine are both components of approved antimalarials with in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). In vitro activity does not always translate to clinical efficacy across a therapeutic dose range. This study applied available, verified, physiologically based pharmacokinetic (PBPK) models for pyronaridine, amodiaquine, and its active metabolite N‐desethylamodiaquine (DEAQ) to predict drug concentrations in lung tissue relative to plasma or blood in the default healthy virtual population. Lung exposures were compared to published data across the reported range of in vitro EC50 values against SARS‐CoV‐2. In the multicompartment permeability‐limited PBPK model, the predicted total Cmax in lung mass for pyronaridine was 34.2 μM on Day 3, 30.5‐fold greater than in blood (1.12 μM) and for amodiaquine was 0.530 μM, 8.83‐fold greater than in plasma (0.060 μM). In the perfusion‐limited PBPK model, the DEAQ predicted total Cmax on Day 3 in lung mass (30.2 μM) was 21.4‐fold greater than for plasma (1.41 μM). Based on the available in vitro data, predicted drug concentrations in lung tissue for pyronaridine and DEAQ, but not amodiaquine, appeared sufficient to inhibit SARS‐CoV‐2 replication. Simulations indicated standard dosing regimens of pyronaridine‐artesunate and artesunate‐amodiaquine have potential to treat COVID‐19. These findings informed repurposing strategies to select the most relevant compounds for clinical investigation in COVID‐19. Clinical data for model verification may become available from ongoing clinical studies.Keywords
This publication has 45 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host responseDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved DrugsAntimicrobial Agents and Chemotherapy, 2020
- Design and synthesis of new lupeol derivatives and their α-glucosidase inhibitory and cytotoxic activitiesNatural Product Research, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis DrugsCPT: Pharmacometrics & Systems Pharmacology, 2015
- Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai SubjectsAntimicrobial Agents and Chemotherapy, 2015
- Pharmacokinetic Interaction between Pyronaridine-Artesunate and MetoprololAntimicrobial Agents and Chemotherapy, 2014
- Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2014
- Effect of dose size on amodiaquine pharmacokinetics after oral administrationEuropean Journal of Clinical Pharmacology, 1987
- The disposition of amodiaquine in man after oral administration.British Journal of Clinical Pharmacology, 1987